US FDA Moves Homeopathic Drug Enforcement To Risk-Based Approach
This article was originally published in The Pink Sheet
Executive Summary
Products with routes of administration other than oral and topical or intended to be used for the prevention or treatment of serious or life-threatening diseases and conditions will be among those prioritized for enforcement and "regulatory actions," draft guidance notes.